HIV Infections - Complications
Research News and Information

Sunday, November 22, 2009

A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus.

30 Oct 2009 OBJECTIVE: Study aimed to assess safety, tolerability, and immunogenicity of novel therapeutic HPV-16 E6E7 ISCOMATRIX vaccine for treatment of human papilloma virus (HPV)-related anal intraepithelial neoplasia in HIV-infected men who have sex with ... Read more...

Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study.

30 Oct 2009 OBJECTIVES: Recent studies have suggested that highly active antiretroviral therapy may lead to rises in alanine transaminase (ALT) among HIV-infected patients. However, the definition of an ALT flare is arbitrary and the extent to which such ... Read more...

A review of rotavirus infection in and vaccination of human immunodeficiency virus-infected children.

30 Oct 2009 Diarrhea caused by infection with rotavirus annually results in an estimated 611,000 deaths among infants and young children <5 years of age worldwide, and these deaths primarily occur in developing countries. Infection with human immunodeficiency ... Read more...

Latest indexed articles for 'HIV Infections - Complications'

These are the very latest articles for this heading:

• Infection of T lymphocytes in non-Asian patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. 13 Dec 2009
• HIV/AIDS and diabetes: minimizing risk, optimizing care. 29 Nov 2009
• Making the most of your medical visits. 29 Nov 2009
• A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. 30 Oct 2009
• Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. 30 Oct 2009
• Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients. 30 Oct 2009
• A review of rotavirus infection in and vaccination of human immunodeficiency virus-infected children. 30 Oct 2009
• Male circumcision and risk of HIV in women. 29 Oct 2009
• Downregulation of MIP-1alpha/CCL3 with praziquantel treatment in Schistosoma haematobium and HIV-1 co-infected individuals in a rural community in Zimbabwe. 21 Oct 2009
• Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. 13 Oct 2009
• Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. 13 Oct 2009
• Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. 13 Oct 2009
• Effect of vitamin D on tuberculosis and HIV replication depends on conversion to calcitriol and concentration. 13 Oct 2009
• Reflections: neurology and the humanities: reflections for October. 11 Oct 2009
• Medical image. Combined surgery and repeated angioembolisation for a post-pancreatitis pseudoaneurysm. 7 Oct 2009
• Aspects of herpes simplex virus: a clinical review. 29 Sep 2009
• HIV-specific health care utilization and mortality among tuberculosis/HIV coinfected persons. 29 Sep 2009
• Consequences of drug abuse and HIV/AIDS in China: recommendations for integrated care of HIV-infected drug users. 29 Sep 2009
• Serum (1-->3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. 29 Sep 2009
• Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. 29 Sep 2009

See a longer list of these articles.

Technical information about 'HIV Infections'

Definition: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).

Descriptor UI: D015658

Alternative terms: HIV Infections; HIV Infection; Infection, HIV; Infections, HIV; HTLV-III-LAV Infections; HTLV III LAV Infections; HTLV-III-LAV Infection; Infection, HTLV-III-LAV; Infections, HTLV-III-LAV; T-Lymphotropic Virus Type III Infections, Human; T Lymphotropic Virus Type III Infections, Human; HTLV-III Infections; HTLV III Infections; HTLV-III Infection; Infection, HTLV-III; Infections, HTLV-III;

Related Mesh Headings: Lymphoma, AIDS-Related;

Allowable Qualifiers: blood; cerebrospinal fluid; chemically induced; classification; complications; congenital; diagnosis; diet therapy; drug therapy; economics; embryology; enzymology; ethnology; etiology; genetics; history; immunology; metabolism; microbiology; mortality; nursing; epidemiology; parasitology; pathology; physiopathology; prevention & control; psychology; radiography; radionuclide imaging; radiotherapy; rehabilitation; surgery; therapy; transmission; urine; veterinary; ultrasonography; virology;

Tree Number: C02.782.815.616.400; C02.800.801.400; C20.673.480;

Online Note: use ACQUIRED IMMUNODEFICIENCY SYNDROME to search HUMAN T-LYMPHOTROPIC VIRUS TYPE III INFECTION 1989; HIV INFECTION 1988-89; HTLV-III INFECTION & HTLV-III LAV INFECTION 1987-89

History Note: 90; T-LYMPHOTROPIC VIRUS TYPE III INFECTION, HUMAN was HUMAN T-LYMPHOTROPIC VIRUS TYPE III INFECTION see ACQUIRED IMMUNODEFICIENCY SYNDROME 1989; HIV INFECTION was see ACQUIRED IMMUNODEFICIENCY SYNDROME 1988-89; HTLV-III INFECTION & HTLV-III-LAV INFECTION were see ACQUIRED IMMUNODEFICIENCY SYNDROME 1987-89

Technical Notes: caused by a lentivirus; GEN or unspecified; coord IM with HIV-1 (IM) or HIV-2 (IM); note specific indentions under HIV INFECTIONS; DF: HIV INFECT